BridgeMD
New treatment option for Bladder Cancer
Official title Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA
ClinicalTrials.gov ID: NCT07413523
What this study is testing
- What it's testing
- Bladder cancer is the most common type of urothelial cancer. When the disease has spread to other parts of the body (metastatic disease), the prognosis is often poor, because there are only a few effective treatment options available.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age \> 18 years
- WHO performance status ≤ 2
- Pathological proven urothelial carcinoma
- Stage IV disease at imaging
- Maximum of 3 extracranial metastases
You likely can't join if
- Inability to provide informed consent
- Previous radiation therapy on the same target lesions
- Pregnant or breastfeeding patients
- Prior malignancy within the last five years (except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the skin or in situ...
- Mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study
- WHO PS \>=3
See the full eligibility criteria
- Age \> 18 years
- WHO performance status ≤ 2
- Pathological proven urothelial carcinoma
- Stage IV disease at imaging
- Maximum of 3 extracranial metastases
- Indication to receive I or II line of standard systemic therapy
- Adequate liver function
- Adequate bone marrow function
- Written informed consent
- Inability to provide informed consent
- Previous radiation therapy on the same target lesions
- Pregnant or breastfeeding patients
- Prior malignancy within the last five years (except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the skin or in situ carcinoma of the cervix, surgically cured, or localized prostate cancer...
- Mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study
- WHO PS \>=3
The study team makes the final eligibility decision.
Where it's taking place
- Rozzano, Milan, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rozzano, Milan, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.